Introduction

Vesicular stomatitis virus (VSV) has long been a useful research tool in virology and recently become an essential part of medicinal products. Vesiculovirus research is growing quickly following its adaptation to clinical gene and cell therapy and oncolytic virotherapy.

Areas covered

This article reviews the versatility of VSV as a research tool and biological reagent, its use as a viral and vaccine vector delivering therapeutic and immunogenic transgenes and an oncolytic virus aiding cancer treatment. Challenges such as the immune response against such advanced therapeutic medicinal products and manufacturing constraints are also discussed.

Expert opinion

The field of in vivo gene and cell therapy is advancing rapidly with VSV used in many ways. Comparison of VSV’s use as a versatile therapeutic reagent unveils further prospects and problems for each application. Overcoming immunological challenges to aid repeated administration of viral vectors and minimizing harmful host–vector interactions remains one of the major challenges. In the future, exploitation of reverse genetic tools may assist the creation of recombinant viral variants that have improved onco-selectivity and more efficient vaccine vector activity. This will add to the preferential features of VSV as an excellent advanced therapy medicinal product (ATMP) platform.

中文翻译：

---

具有多种应用的工具：研究和医学中的水疱性口炎病毒。

介绍

水泡性口炎病毒（VSV）长期以来一直是病毒学中的有用研究工具，最近已成为医药产品的重要组成部分。适应于临床基因和细胞疗法以及溶瘤病毒疗法的病毒病毒研究正在迅速发展。

覆盖区域

本文综述了VSV作为研究工具和生物试剂的多功能性，将其用作提供治疗性和免疫原性转基因的病毒和疫苗载体，以及协助癌症治疗的溶瘤病毒。还讨论了诸如对此类先进治疗药物的免疫应答和制造限制等挑战。

专家意见

通过多种方式使用的VSV ，体内基因和细胞治疗领域正在迅速发展。VSV用作通用治疗试剂的比较揭示了每种应用的进一步前景和问题。克服免疫学挑战，以帮助病毒载体的重复给药，并使有害的宿主与载体之间的相互作用最小化，仍然是主要挑战之一。将来，反向遗传工具的开发可能有助于创建重组病毒变异体，这些变异体具有提高的癌选择性和更有效的疫苗载体活性。这将增加VSV作为出色的先进治疗药物（ATMP）平台的优先功能。